Raffaele Colombo, Director of Medicinal Chemistry at Zymeworks Inc., shared a post on X:
“Recent publication of T-Bren on eBioMedicine:
Surprisingly, half-life (2.6 days) of T-Bren is relatively short compared to other topo1i trastuzumab ADCs!
(PK of Topo1 T-ADC from the article, updated with T-Bren)”
1. Title: A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody–drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours
Authors: Herui Yao, Ruihua Zhao, Xiuping Lai, Qing Wen, Meili Sun, Ying Wang, Suiwen Ye, Jun Jia, Ling Guan, Yongqiang Zhang, Xian Wang, Yahua Zhong, Jianying Huang, Mei Li, Junlan Guo, Fuguo Tian, Yuan Yuan, Sa Xiao, Hai Zhu, Yi Zhu, Rongbo Lin, Hong Zong, Erwei Song
Quoting an older post:
“In our Annals of Oncology review we collected (see supplementary figure S6) available PK of trastuzumab-based ADCs with different drug-linkers compared to ‘naked’ trastuzumab!
(divided by payload classes)”
2. Title: Re-evaluating antibody–drug conjugate linker stability: assessment, interpretation, and clinical translation
Authors: R. Colombo, S.D. Seredick, S.D. Barnscher, J.R. Rich
Other articles featuring Raffaele Colombo on OncoDaily.